Zygel Led to Meaningful Behavioral Improvements in Certain Youngsters

Zygel Led to Meaningful Behavioral Improvements in Certain Youngsters

294003

Zygel Led to Meaningful Behavioral Improvements in Certain Youngsters

Zynerba Pharmaceuticals’ experimental cannabidiol (CBD) gel Zygel results in statistically significant and clinically meaningful reductions in behavioral symptoms in children and adolescents with fragile X syndrome (FXS) and a fully methylated FMR1 gene, according to data from the Phase 2/3 CONNECT-FX trial. DNA methylation is a biochemical modification that “turns off” genes,  preventing the production of the respective protein. In this case, methylation of 90% or more of the FMR1 gene (classified as full methylation) is associated with…

You must be logged in to read/download the full post.